Racial and Ethnic Differences in All-Cause and Cardiovascular Disease Mortality: The MESA Study.
cardiovascular diseases
ethnic and racial minorities
health status disparities
social determinants of health
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
19 07 2022
19 07 2022
Historique:
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
26
7
2022
Statut:
ppublish
Résumé
Despite improvements in population health, marked racial and ethnic disparities in longevity and cardiovascular disease (CVD) mortality persist. This study aimed to describe risks for all-cause and CVD mortality by race and ethnicity, before and after accounting for socioeconomic status (SES) and other factors, in the MESA study (Multi-Ethnic Study of Atherosclerosis). MESA recruited 6814 US adults, 45 to 84 years of age, free of clinical CVD at baseline, including Black, White, Hispanic, and Chinese individuals (2000-2002). Using Cox proportional hazards modeling with time-updated covariates, we evaluated the association of self-reported race and ethnicity with all-cause and adjudicated CVD mortality, with progressive adjustments for age and sex, SES (neighborhood SES, income, education, and health insurance), lifestyle and psychosocial risk factors, clinical risk factors, and immigration history. During a median of 15.8 years of follow-up, 22.8% of participants (n=1552) died, of which 5.3% (n=364) died of CVD. After adjusting for age and sex, Black participants had a 34% higher mortality hazard (hazard ratio [HR], 1.34 [95% CI, 1.19-1.51]), Chinese participants had a 21% lower mortality hazard (HR, 0.79 [95% CI, 0.66-0.95]), and there was no mortality difference in Hispanic participants (HR, 0.99 [95% CI, 0.86-1.14]) compared with White participants. After adjusting for SES, the mortality HR for Black participants compared with White participants was reduced (HR, 1.16 [95% CI, 1.01-1.34]) but still statistically significant. With adjustment for SES, the mortality hazards for Chinese and Hispanic participants also decreased in comparison with White participants. After further adjustment for additional risk factors and immigration history, Hispanic participants (HR, 0.77 [95% CI, 0.63-0.94]) had a lower mortality risk than White participants, and hazard ratios for Black participants (HR, 1.08 [95% CI, 0.92-1.26]) and Chinese participants (HR, 0.81 [95% CI, 0.60-1.08]) were not significantly different from those of White participants. Similar trends were seen for CVD mortality, although the age- and sex-adjusted HR for CVD mortality for Black participants compared with White participants was greater than all-cause mortality (HR, 1.72 [95% CI, 1.34-2.21] compared with HR, 1.34 [95% CI, 1.19-1.51]). These results highlight persistent racial and ethnic differences in overall and CVD mortality, largely attributable to social determinants of health, and support the need to identify and act on systemic factors that shape differences in health across racial and ethnic groups.
Sections du résumé
BACKGROUND
Despite improvements in population health, marked racial and ethnic disparities in longevity and cardiovascular disease (CVD) mortality persist. This study aimed to describe risks for all-cause and CVD mortality by race and ethnicity, before and after accounting for socioeconomic status (SES) and other factors, in the MESA study (Multi-Ethnic Study of Atherosclerosis).
METHODS
MESA recruited 6814 US adults, 45 to 84 years of age, free of clinical CVD at baseline, including Black, White, Hispanic, and Chinese individuals (2000-2002). Using Cox proportional hazards modeling with time-updated covariates, we evaluated the association of self-reported race and ethnicity with all-cause and adjudicated CVD mortality, with progressive adjustments for age and sex, SES (neighborhood SES, income, education, and health insurance), lifestyle and psychosocial risk factors, clinical risk factors, and immigration history.
RESULTS
During a median of 15.8 years of follow-up, 22.8% of participants (n=1552) died, of which 5.3% (n=364) died of CVD. After adjusting for age and sex, Black participants had a 34% higher mortality hazard (hazard ratio [HR], 1.34 [95% CI, 1.19-1.51]), Chinese participants had a 21% lower mortality hazard (HR, 0.79 [95% CI, 0.66-0.95]), and there was no mortality difference in Hispanic participants (HR, 0.99 [95% CI, 0.86-1.14]) compared with White participants. After adjusting for SES, the mortality HR for Black participants compared with White participants was reduced (HR, 1.16 [95% CI, 1.01-1.34]) but still statistically significant. With adjustment for SES, the mortality hazards for Chinese and Hispanic participants also decreased in comparison with White participants. After further adjustment for additional risk factors and immigration history, Hispanic participants (HR, 0.77 [95% CI, 0.63-0.94]) had a lower mortality risk than White participants, and hazard ratios for Black participants (HR, 1.08 [95% CI, 0.92-1.26]) and Chinese participants (HR, 0.81 [95% CI, 0.60-1.08]) were not significantly different from those of White participants. Similar trends were seen for CVD mortality, although the age- and sex-adjusted HR for CVD mortality for Black participants compared with White participants was greater than all-cause mortality (HR, 1.72 [95% CI, 1.34-2.21] compared with HR, 1.34 [95% CI, 1.19-1.51]).
CONCLUSIONS
These results highlight persistent racial and ethnic differences in overall and CVD mortality, largely attributable to social determinants of health, and support the need to identify and act on systemic factors that shape differences in health across racial and ethnic groups.
Identifiants
pubmed: 35861763
doi: 10.1161/CIRCULATIONAHA.122.059174
pmc: PMC9937428
mid: NIHMS1815015
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-239Subventions
Organisme : NHLBI NIH HHS
ID : 75N92020D00002
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00005
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95163
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001079
Pays : United States
Organisme : NIMHD NIH HHS
ID : P60 MD002249
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95164
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95168
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES007033
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95165
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95159
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00007
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95167
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC095160
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95160
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL071759
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00001
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95169
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95162
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00003
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95161
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001420
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00004
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00006
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95166
Pays : United States
Références
Ann Epidemiol. 2016 Jun;26(6):429-435.e1
pubmed: 27221804
Circulation. 2016 Aug 16;134(7):504-13
pubmed: 27528645
Glob Heart. 2016 Sep;11(3):269-274
pubmed: 27741974
Nephrol Dial Transplant. 2011 Jun;26(6):1909-16
pubmed: 21051500
Annu Rev Public Health. 2019 Apr 1;40:105-125
pubmed: 30601726
Circulation. 2017 Jul 11;136(2):152-166
pubmed: 28696265
Stroke. 2014 Aug;45(8):2318-23
pubmed: 25013018
J Epidemiol Community Health. 2015 Oct;69(10):1006-11
pubmed: 26034046
J Epidemiol Community Health. 2013 Oct;67(10):846-53
pubmed: 23868527
Am J Epidemiol. 2009 Feb 15;169(4):444-54
pubmed: 19075250
Glob Heart. 2016 Sep;11(3):365-367
pubmed: 27741983
JAMA. 1993 Nov 24;270(20):2464-8
pubmed: 8031341
Circulation. 2005 Sep 13;112(11):1557-65
pubmed: 16144996
BMC Cardiovasc Disord. 2015 Dec 03;15:161
pubmed: 26631068
Circulation. 2018 Jul 3;138(1):e1-e34
pubmed: 29794080
PLoS One. 2016 Nov 22;11(11):e0165651
pubmed: 27875557
Am J Epidemiol. 2017 Aug 15;186(4):445-455
pubmed: 28407040
SSM Popul Health. 2020 Jul 23;11:100634
pubmed: 32775593
SSM Popul Health. 2017 Feb 02;3:245-254
pubmed: 29349222
Diabetes Care. 2008 Aug;31(8):1621-8
pubmed: 18458142
Am J Public Health. 2008 Nov;98(11):1963-70
pubmed: 18511718
Circulation. 2017 Nov 21;136(21):e393-e423
pubmed: 29061565
Glob Heart. 2016 Sep;11(3):353-363
pubmed: 27741982
Stroke. 2020 Nov;51(11):3433-3439
pubmed: 33104471
JAMA. 2012 Nov 7;308(17):1775-84
pubmed: 23117778
J Health Psychol. 1997 Jul;2(3):335-51
pubmed: 22013026
Am Heart J. 2000 Jan;139(1 Pt 1):1-9
pubmed: 10618555
Am J Epidemiol. 2008 Jun 1;167(11):1349-57
pubmed: 18367469
Am J Hypertens. 2004 Oct;17(10):963-70
pubmed: 15485761
Psychol Aging. 1996 Jun;11(2):207-13
pubmed: 8795049
Am J Epidemiol. 2002 Nov 1;156(9):871-81
pubmed: 12397006
J Am Heart Assoc. 2019 Jan 8;8(1):e010603
pubmed: 30563392
Am J Hypertens. 2007 Apr;20(4):354-63
pubmed: 17386340
Circulation. 2010 Feb 2;121(4):586-613
pubmed: 20089546
Circulation. 2014 Aug 12;130(7):593-625
pubmed: 25098323
Circulation. 2019 Apr 2;139(14):1688-1697
pubmed: 30712378
Circulation. 2007 Nov 20;116(21):2383-90
pubmed: 18025402
J Am Heart Assoc. 2021 Apr 20;10(8):e019828
pubmed: 33834848
Biostatistics. 2014 Apr;15(2):222-33
pubmed: 24292992
Lancet. 2016 Aug 13;388(10045):696-704
pubmed: 27233746
Am J Hypertens. 2011 Feb;24(2):187-93
pubmed: 20847728
Int J MCH AIDS. 2017;6(2):139-164
pubmed: 29367890
JAMA. 2018 Oct 16;320(15):1531-1532
pubmed: 30264132
JAMA Intern Med. 2015 Aug;175(8):1311-20
pubmed: 26121402
Am J Clin Nutr. 2009 Sep;90(3):647-54
pubmed: 19625679
Circ Heart Fail. 2016 Jan;9(1):e002243
pubmed: 26699386
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848